Search

Your search keyword '"Tanguay, Simon"' showing total 811 results

Search Constraints

Start Over You searched for: Author "Tanguay, Simon" Remove constraint Author: "Tanguay, Simon"
811 results on '"Tanguay, Simon"'

Search Results

2. Association of Cabozantinib Dose Reductions for Toxicity With Clinical Effectiveness in Metastatic Renal Cell Carcinoma (mRCC): Results From the Canadian Kidney Cancer Information System (CKCis)

3. Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies

6. A randomized, double-blind, placebo-controlled trial of metformin in reducing progression among men on expectant management for low-risk prostate cancer: The MAST (Metformin Active Surveillance Trial) study.

7. Outcomes of Cytoreductive Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Real World Data from Canadian Centers

11. MP36-13 ASSOCIATION BETWEEN THE SARCOMATOID STATUS AND PERCENTAGE OF SARCOMATOID ON THE CLINICAL OUTCOMES OF LOCALIZED RENAL CELL CARCINOMA POST NEPHRECTOMY

12. PD16-03 UNDERSTANDING THE MOLECULAR CHARACTERISTICS AND VULNERABILITIES OF SARCOMATOID/RHABDOID RENAL CELL CARCINOMAS THROUGH INTEGRATIVE HISTOLOGICAL AND SPATIAL GENOMICS APPROACHES

17. Impact of Timing of Immunotherapy and Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Real-World Data on Survival Outcomes from the CKCis Database.

19. Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies

24. The impact of robotic surgery access on the management of patients with clinical stage I kidney tumors at Canadian academic centers

25. Trends of Utilization of Systemic Therapies for Metastatic Renal Cell Carcinoma in the Canadian Health Care System

26. Adjuvant therapy for renal cell carcinoma

28. Development and Implementation of a Continuing Medical Education Program in Canada: Knowledge Translation for Renal Cell Carcinoma (KT4RCC)

30. External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma

31. Abstract B011: An atlas of cellular heterogeneity in primary and metastatic renal cell carcinomas

34. Abstract PR005: An atlas of cellular heterogeneity in primary and metastatic renal cell carcinomas

37. Impact of timing of immunotherapy and cytoreductive nephrectomy on outcomes in metastatic renal cell carcinoma: Results from the CKCis database.

38. Ipilimumab/nivolumab (I/N) compared to axitinib/pembrolizumab (A/P) in metastatic renal cell carcinoma (mRCC): Insights from a Canadian population.

39. Management, outcomes and predictors of recurrence in chromophobe renal cell carcinoma: Results from the Canadian Kidney Cancer information system (CKCis).

40. Real-world treatment outcomes in patients with advanced renal cell carcinoma who receive axitinib plus pembrolizumab in the first-line setting in Canadian cancer centers.

41. Real-world efficacy and toxicity of ipilimumab and nivolumab as first line treatment of metastatic renal cell carcinoma (mRCC) in a subpopulation of elderly and poor performance status patients.

42. Real-world practice patterns, treatment-related toxicity, and survival outcomes in older patients with metastatic renal cell carcinoma: Results from the Canadian Kidney Cancer information system (CKCis).

43. 2023 UPDATE – Canadian Urological Association guideline: Management of cystic renal lesions: Prior to original publication (March 2017), this guideline underwent review by the CUA Guidelines Committee, CUA members at large, and the CUA Executive Board. The 2023 updates were app roved by the CUA Guidelines Committee and CUA Executive Board

46. 2023 UPDATE – Canadian Urological Association guideline: Management of cystic renal lesions

47. Comparison of patients with renal cell carcinoma in adjuvant therapy trials to a real-world population

48. MP41-03 IS A RENAL TUMOUR BENIGN OR MALIGNANT? A PREDICTION TOOL INCLUDING PATIENTS MANAGED WITH SURGERY, ABLATION, OR SURVEILLANCE

49. PD07-10 OUTCOMES OF PARTIAL NEPHRECTOMY FOR NON-METASTATIC cT2 RENAL TUMORS: RESULTS FROM A CANADIAN MULTI-INSTITUTIONAL COLLABORATIVE

Catalog

Books, media, physical & digital resources